Elicio Therapeutics, Inc. announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (PDAC). ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio?s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by seven common mutations in KRAS (G12D, G12R, G12V, G12A, G12C, G12S and G13D) present in 25% of all solid tumor cancers and 88% of PDAC patients. This is in contrast to other KRAS-targeted therapeutics in development ?

particularly small molecule KRAS inhibitors ? which target fewer mutations, potentially limiting the number of patients that can be treated and also limiting duration of benefit due to development of escape mutants. Elicio will present a Trial in Progress poster on the design of the AMPLIFY-7P trial at the ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 in San Francisco, CA.

Initial interim data on ELI-002 7P monotherapy from Phase 1A arm will be shared in the first half of 2024.